SCHEMBL2468271

SCHEMBL2468271

CCc1ccc(CCNC(=O)C2(Cc3ccccc3)CCN(S(=O)(=O)NCCOC)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 1/20 0.42
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
CHRM5 P08912 1/20 0.40
CHRM3 P20309 1/20 0.40
TAAR1 Q96RJ0 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP3A4 P08684 1/20 0.39
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473023 0.89 FKBP1A (0.44) FKBP1AALDH1A1HPGDKDM4EGAA
SCHEMBL2470430 0.84 MEN1 (0.41) FKBP1AALDH1A1HPGDKDM4EGAA
SCHEMBL2702179 0.84 HPGD (0.41) ALDH1A1HPGDKDM4EGAAHTT
SCHEMBL2472232 0.82 GAA (0.54) FKBP1AALDH1A1GAAHTTKMT2A
SCHEMBL2471780 0.82 MEN1 (0.55) FKBP1AALDH1A1GAACYP2C19KMT2A
SCHEMBL2469084 0.81 KMT2A (0.61) FKBP1AALDH1A1GAAKMT2AMEN1
SCHEMBL2469565 0.80 CYP2D6 (0.50) ALDH1A1HPGDHSD17B10CYP2C19KMT2A
SCHEMBL2472263 0.79 MEN1 (0.59) FKBP1AALDH1A1GAAHTTCYP2C19
SCHEMBL2469016 0.79 KMT2A (0.51) FKBP1AALDH1A1GAAHTTKMT2A
SCHEMBL2472160 0.79 FKBP1A (0.51) FKBP1AALDH1A1GAAHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2371366-A1 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 FKBP1A 1791/4885ALDH1A1 3941/4885HPGD 1527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.